Activity OverviewRheum2Learn 2.0 is case-based, fundamental clinical rheumatology education for residents. Each interactive activity includes three patient cases that focus on the care and assessment of individuals with rheumatologic diseases.Learn about vasculitis, including its presentation, how to diagnosis, and management strategies for giant cell vasculitis and small vessel vasculitis.  Three patient cases will provide information on giant cell arteritis (GCA), leukocytoclastic vasculitis, and complications such as pulmonary-renal syndrome (PRS).Rheum2Learn SeriesThis activity is part of a series. See all activities in the series below.Rheum2Learn 2.0: Crystalline ArthritisRheum2Learn 2.0: Infectious ArthritisRheum2Learn 2.0: Inflammatory MyopathiesRheum2Learn 2.0: Musculoskeletal DisordersRheum2Learn 2.0: Musculoskeletal ExaminationRheum2Learn 2.0: OsteoporosisRheum2Learn 2.0: OsteoarthritisRheum2Learn 2.0: Pediatric RheumatologyRheum2Learn 2.0: Rheumatic Manifestations of Systemic DiseaseRheum2Learn 2.0: Rheumatoid ArthritisRheum2Learn 2.0: SpondyloarthritisRheum2Learn 2.0: Sjögren’s DiseaseRheum2Learn 2.0: Systemic Lupus ErythematosusRheum2Learn 2.0: Systemic SclerosisRheum2Learn 2.0: Systemic VasculitisRegistration is complimentary.Target AudienceResidents in training who may provide care for patients with rheumatic diagnoses in primary care, inpatient, critical care, and other clinical contexts.The activity may also be of interest to medical students, fellows in training, advanced practice providers, practicing physicians, and other health care professionals who seek to strengthen their clinical knowledge of rheumatic diseases.Learning ObjectivesUpon completion of this activity, participants should be able to:Identify the clinical manifestations concerning for cranial giant cell arteritis (GCA)Understand the potential complications associated with delay in diagnosisDevelop a first line management planDistinguish different etiologies of lower extremity rash in order to identify palpable purpuraOutline the differential diagnosis for underlying etiologies of leukocytoclastic vasculitisDetermine when systemic treatment is warranted for leukocytoclastic vasculitis limited to cutaneous involvementRecognize that pulmonary-renal syndrome (PRS) is a medical emergencyDescribe the most common etiologies of pulmonary-renal syndrome (PRS)Understand aggressive therapy should be instituted in a timely fashionCE & MOC InformationThis activity is not eligible for CME/MOC.Acknowledgement of Commercial SupportNo commercial support was provided for this activity.Educational Activity PoliciesSee ACR educational activity policies, including the online enduring activity refund policy.

Activity OverviewThe Advanced Rheumatology Course is a 19-activity series for advanced practice providers and other professionals who need a deeper dive into rheumatology.  The series covers how to assess and manage patients with rheumatic disease, develop strategies to integrate NP/PAs into rheumatology practice, and improve access to care for patients. The advanced information will help experienced practice providers function well in rheumatology and foster inter-professional collaboration. In this activity, you will review the epidemiology, clinical features, differential diagnoses, treatment options, and outcomes concerning vasculitis and other vasculitides.Advanced Rheumatology Course SeriesThis activity is part of a series. See the other activities in the series below.Advanced Rheumatology Course: All ActivitiesARC01: Musculoskeletal Structure And Function And Inflammation And ImmunityARC02: Framework for Clinical Decision Making in RheumatologyARC03: Laboratory Evaluation of Rheumatic DiseaseARC04: Imaging of ArthritisARC05: Coding and Practice IssuesARC06: Therapeutic Interventions And ResourcesARC07: OsteoarthritisARC08: RA and Seronegative Inflammatory ArthropathiesARC09: Systemic Lupus ErythematosusARC010: Systemic Inflammatory Conditions: Inflammatory MyopathyARC11: Vasculitis, Arteritis and PMRARC12: Crystal-Induced ArthropathiesARC13: Pain SyndromesARC14: SpondyloarthritisARC15: Infection-Related ArthritisARC16: Osteoporosis And Other Metabolic Bone DisordersARC17: Comprehensive Overview of Juvenile Idiopathic Arthritis (JIA)ARC18:Comprehensive Overview of Pediatric Connective Tissue Diseases (CTD)ARC19: Pediatric Noninflammatory Musculoskeletal PainRegistration is discounted for ACR/ARP members. If you are not a member, consider joining ACR/ARP.Target AudienceAdvanced practice nurses and physician assistants. Fellows-in training, residents, students, primary care providers, physical therapists, and researchers may also benefit.Learning ObjectivesUpon completion of this activity, participants should be able to: Define vasculitis and describe the clinical features and the spectrum of disease entities in which vasculitis is seenDescribe the epidemiology, clinical features, differential diagnosis, treatment, and outcome for polymyalgia rheumatica (PMR)Describe the epidemiology, clinical features, differential diagnosis, treatment, and outcome of giant cell arteritis (GCA)Describe the epidemiology, clinical features, differential diagnosis, treatment, and outcome of granulomatosis with polyangiitis (GPA)Describe the epidemiology, clinical features, differential diagnosis, treatment, and outcome of polyarteritis nodosaDescribe cutaneous vasculitis and its potential causes, diagnostic evaluation, and therapeutic principlesCE & MOC InformationACCME Accreditation StatementThe American College of Rheumatology (ACR) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.AMA Designation StatementThe American College of Rheumatology designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.See the ACR's CME Mission Statement. For more information, download the AMA PRA Booklet.CME credit must be claimed by August 14, 2026, at 11:59 PM ET.Financial Relationship DisclosuresACR Disclosure StatementIt is the policy of the American College of Rheumatology (ACR) to ensure that Continuing Medical Education (CME) activities are independent and free of commercial bias. To ensure educational content is objective, balanced, and guarantee content presented is in the best interest of its learners' and the public, the ACR requires that everyone in a position to control educational content disclose all financial relationships with ineligible companies within the prior 24 months. An ineligible company is one whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients. Examples can be found at accme.org.In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, ACR has implemented mechanisms prior to the planning and implementation of this CME activity to identify and mitigate all relevant financial relationships for all individuals in a position to control the content of this CME activity.Nature of Financial RelationshipsAll individuals that participate in an ACR-sponsored activity and are able to change content or influence the content of the activity must disclose to the planning committee and audience all financial or other relationships with ineligible companies including, but not limited to: Advisor or review panel memberConsultantEmployeeOfficer or Board MemberGrant/research supportSpeaker/honoraria includes speaker’s bureau, symposia, and expert witnessIndependent contractorExecutive role and/or ownership interestRoyalties and/or patent beneficiaryIntellectual property/patentsStock options or bond holdings in a for-profit corporation or self-directed pension planPrivate investigatorExpert witnessEquity interestOther: specify detailsNone: Has no relevant financial relationship(s) with ineligible companies to disclose.All participants that created and/or were able to influence the content and delivery of this activity reported the following disclosures. All of the relevant financial relationships listed have been mitigated.Authors/PlannersAnisha Dua, MD - AbbVie/Abbott5, 8; ChemoCentryx5; Novartis5Josh Waytz, MD – No relevant financial relationships to discloseEditors and ReviewersPaul Monach, MD, PhD – Celgene1; Chemocentryx6; KiniksaAnneke Smith – No relevant financial relationships to discloseMarcy Bolster, MD – AbbVie2; American Board of Internal Medicine: Chair, ABIM Rheumatology Board6; Amgen2; Corbus Pharmaceuticals2; Cumberland2; Genentech2; Gilead Sciences5; Johnson & Johnson1; Pfizer2Acknowledgement of Commercial SupportThe project was supported by Grant number 1 NU58DP006908-03-00 – Component A; Developing and Disseminating Programs to Build Sustainable Lupus Awareness, Knowledge, Skills and Partnerships. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the Department of Health and Human Services, Centers for Disease Control and Prevention.Educational Activity PoliciesSee ACR educational activity policies, including the online enduring activity refund policy.